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Abstract
We tested the hypothesis that long-term caffeine intake prevents the development of insulin resistance and hypertension in two pathologi-
cal animal models: the high-fat (HF) and the high-sucrose (HSu) diet rat. We used six groups of animals: control; caffeine-treated (Caff; 1 g/l
in drinking water during 15 d); HF; caffeine-treated HF (HFCaff); HSu; caffeine-treated HSu (HSuCaff). Insulin sensitivity was assessed using
the insulin tolerance test. Blood pressure, weight gain, visceral fat, hepatic glutathione, plasma caffeine, insulin and NO, and serum NEFA
and catecholamines were measured. Caffeine reversed insulin resistance and hypertension induced by both the HF and HSu diets. In the
HF-fed animals caffeine treatment restored fasting insulin levels to control values and reversed increased weight gain and visceral fat mass.
In the HSu group, caffeine reversed fasting hyperglycaemia and restored NEFA to control values. There were no changes either in plasma
NO or in hepatic glutathione levels. In contrast, caffeine totally prevented the increase in serum catecholamines induced by HF and HSu
diets. To test the hypothesis that inhibition of the sympathetic nervous system prevents the development of diet-induced insulin resistance
we administered carvedilol, an antagonist of b1, b2 and also a1 adrenoceptors, to HF and HSu rats. Carvedilol treatment fully prevented
diet-induced insulin resistance and hypertension, mimicking the effect of caffeine. We concluded that long-term caffeine intake prevented
the development of insulin resistance and hypertension in HF and HSu models and that this effect was related to a decrease in circulating
catecholamines.
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Insulin resistance and hypertension are core metabolic
abnormalities in highly prevalent diseases such as type 2 dia-
betes, the metabolic syndrome and obstructive sleep
apnoea(1). Drug development for these diseases has focused
on reversal strategies, while preventive interventions are
mainly related to lifestyle changes. One of the lifestyle modi-
fications advised is to limit caffeine intake, based on several
studies describing that caffeine acutely increases blood press-
ure(2) and lowers insulin sensitivity(3,4). Recently, the benefits
of caffeine withdrawal have been questioned, since a
number of epidemiological studies showed no association
between long-term coffee consumption, type 2 diabetes
risk(5,6) and high blood pressure(7–10), which confirms that
acute and chronic caffeine intakes have opposite effects(11,12).
Besides the discussion on the protective v. deleterious
effects of coffee in type 2 diabetes and hypertension, there
is also controversy concerning the nature of the compound
involved in it. Some authors claim that the beneficial effects
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of coffee are mediated by caffeine(5,13,14) while others support
that coffee components, apart from caffeine, are responsible
for the protection against type 2 diabetes and cardiovascular
disease(7,15,16). Regarding the protective role of caffeine
intake in the development of type 2 diabetes, the primary
mechanism proposed is weight loss attributed to increased
thermogenesis, lipolysis and fat oxidation induced by the
drug(5,13,14,17); still this hypothesis remains debatable since it
has also been observed that long-term coffee consumption
does not cause significant weight reduction(18).
Sporadic caffeine intake has also been correlated with elev-
ated blood pressure(2,19–21) due to sympathetic over-activation
by increased catecholamine levels and down-regulation of
b-receptors(22), antagonism of adenosine receptors(23),
increased noradrenaline release via direct effects on the adre-
nal medulla and activation of the renin–angiotensin system(9).
However, though caffeine administration raises blood press-
ure acutely, tolerance to this effect develops rapidly, and
heavy coffee drinkers are less likely to show an increase
in blood pressure after caffeine intake(24,25). In fact, recent
prospective studies even suggest a protective role of high
coffee intake against hypertension(9).
In the present study, we tested the effects of long-term
caffeine intake, at a dose equivalent to moderate human
consumption that was previously shown to produce plasma
caffeine levels comparable with those in moderate consumers
of caffeinated beverages(26,27) in the prevention of diet-
induced insulin sensitivity and hypertension in two pathologi-
cal animal models, the high-sucrose diet rat and the high-fat
diet rat. We found that chronic caffeine consumption
prevented the development of insulin resistance and hyper-
tension and led to a decrease in circulating catecholamines
in the pathological animal models tested. The present results
also showed that the pharmacological inhibition of the sym-
pathetic nervous system with carvedilol (CVD), an antagonist
of a1, b1 and b2 adrenoceptors, prevented diet-induced
insulin resistance in high-sucrose diet and high-fat diet rats
similarly to caffeine. We propose that long-term caffeine
administration has a protective effect on the development of
diet-induced insulin resistance and hypertension through a
decrease in circulating catecholamines.
Methods
Animals and experimental procedures
Experiments were performed in male and female Wistar
rats (weight 200–420 g), aged 3 months, obtained from
the vivarium of the Faculdade de Ciências Médicas. The
animals were kept under temperature and humidity control
(21 ^ 18C; 55 ^ 10 % humidity) with a 12 h light–12 h
dark cycle.
Rats were divided into six groups: (1) control group; (2)
caffeine group (Caff); (3) high-fat diet group (HF), a model
of the metabolic syndrome(28); (4) high-fat diet combined
with caffeine intake group (HFCaff); (5) high-sucrose diet
group (HSu), a lean model of combined insulin resistance
and hypertension(29); (6) the high-sucrose diet combined
with caffeine intake group (HSuCaff).
The control group was fed standard chow (7·4 % fat þ75 %
carbohydrate (4 % sugar) þ17 % protein; SDS diets RM1;
Probiológica, Sintra, Portugal); the HF group was fed a lipid-
rich diet (45 % fat þ35 % carbohydrate þ20 % protein;
Mucedola, Settimo Milanese, Italy) for 21 d; the HSu group
was fed standard chow and drank 35 % sucrose (Panlab,
Lisbon, Portugal) for 28 d. We chose to submit the HSu rats to
a 28 d high-sucrose treatment, since at 21 d the animals were
neither insulin resistant nor hypertensive (data not shown).
Caffeine (1 g/l) was administered in drinking water during the
last 15 d of the experimental protocol(30). In the HSuCaff group,
sucrose and caffeine were administered in the same bottle.
A second set of experiments was performed to test if the
effect of sympathetic blockade on insulin sensitivity was simi-
lar to the effect of caffeine in the pathological animal models
tested. CVD, an antagonist of a1, b1 and b2 adrenoceptors,
was the drug of choice and it was administered at a dose of
0·2 g/l in a 0·5 % methylcellulose solution in the drinking
bottles, during the last 15 d of the experimental protocol.
Methylcellulose was used to facilitate dissolution of CVD
and absorption of the drug(31).
Rats were also divided into six groups: (1) the control group
administered the vehicle, 0·5 % methylcellulose in drinking
water (MC); (2) the CVD group; (3) the HF group administered
the vehicle (HFMC); (4) the HF group treated with CVD
(HFCVD); (5) the HSu group administered the vehicle
(HSuMC); (6) the HSu group treated with CVD (HSuCVD).
Individual daily liquid intake was measured to monitor caf-
feine and CVD ingestion. Body weight was assessed twice
per week. On the last day of the experimental protocol, rats
were fasted overnight and allowed free access to caffeine
solutions or water. Afterwards, the animals were anaesthetised
with intraperitoneal sodium pentobarbital (60 mg/kg) and
transferred to a heating pad to maintain body temperature at
37·5 ^ 0·58C throughout the experiment. Animals were eutha-
nised by an intracardiac overdose of pentobarbital.
Principles of laboratory care were followed in accordance
with the European Union Directive for Protection of Ver-
tebrates Used for Experimental and Other Scientific Ends
(86/609/CEE). Experimental protocols were previously
approved by the Ethics Committee for Animal Care and Use
at the Faculty of Medical Sciences, New University of Lisbon
(FCM-UNL; Faculdade de Ciências Médicas, Universidade
Nova de Lisboa).
Measurement of insulin sensitivity
The insulin tolerance test (ITT) was used to measure insulin
sensitivity. The ITT is one of the earliest methods developed
to assess insulin sensitivity in vivo and provides an estimate
of overall insulin sensitivity, correlating well with the ‘gold
standard’ hyperinsulinaemic–euglycaemic clamp(32). The ITT
consists of the administration of an intravenous insulin bolus
of 0·1 U (4·5mg)/kg body weight, after an overnight fast, fol-
lowed by the measure of the decline in plasma glucose con-
centration over 15 min at 1 min intervals. The constant rate

















for glucose disappearance (KITT) was calculated using the
formula 0·693/t1/2. Glucose half-time (t1/2) was calculated
from the slope of the least-square analysis of plasma glucose
concentrations during the linear decay phase. Blood samples
were collected by tail tipping and glucose levels were
measured with a Glucose Analyzer (1500 YSI Sport; Yellow
Springs Instruments, Yellow Spring, OH, USA).
Measurement of blood pressure
To measure mean arterial pressure (MAP), the femoral artery
was cannulated under a dissection microscope and the cath-
eter was connected to a pressure transducer and amplifier
(model 603; HSE-HA GmgH, Harvard Apparatus, Madrid,
Spain). MAP data were acquired with HSE-Harvard PULM-
ODYN W software (Harvard Apparatus).
Plasma caffeine quantification
In the caffeine-treated groups, plasma samples, collected
by heart puncture into EDTA precoated tubes, were pre-
treated for protein precipitation with perchloric acid (30 %)
and neutralised with KOH (4 M)–2-amino-2-hydroxymethyl-
propane-1,3-diol (Tris; 0·4 M). Caffeine and its metabolites
theobromine, theophyline and paraxanthine were quantified
by reverse-phase HPLC with low-pressure gradient with UV
detection at 274 nm. The HPLC system consisted of an LC
10-A solvent delivery pump (Shimadzu, Kyoto, Japan), an
automatic injector SIL-20AC (Shimadzu), a SPD-6 AV UV-VIS
wavelength detector (Shimadzu) and Shimadzu Class VP soft-
ware to analyse the chromatograms. A low-pressure gradient
was used: the initial mobile phase consisted of a solution of
50 mM-KH2PO4 (pH 4·58), with 9 % of methanol and 2 % of
acetonitrile running at a flux of 1·5 ml/min. Concentrations
of the organic solvents changed throughout the sample run.
Standards of caffeine, theophylline, theobromine and para-
xanthine were prepared in 5 % of bovine serum albumin
and submitted to the same pre-treatment as the biological
samples. Identification of the peaks in the biological samples
was made by comparison with the retention times of the
standards.
Quantification of blood glucose, insulin, NEFA, nitric
oxide and catecholamines
In all the experiments, plasma and serum were collected by
heart puncture. Insulin, caffeine and NO were determined in
plasma; NEFA and catecholamines were determined in serum.
Insulin was quantified with an ELISA kit (Mercodia Ultrasensi-
tive Rat Insulin ELISA kit; Mercodia AB, Uppsala, Sweden) and
NEFA with a colorimetric assay (Zen-Bio Inc., Research Triangle
Park, NC, USA). For NO/NO3
2 determination, plasma samples
obtained were deproteinised by adding two volumes of
ethanol (08C). NO/NO3
2 concentration was determined by
using a selective and sensitive NO/ozone chemiluminescence
technique (NO-Analyzer 280; Sievers Research Inc., Boulder,
CO, USA). For the quantification of catecholamines in serum,
500ml of serum samples were purified and catecholamines
were extracted using 30 mg OASIS Hlb Wat cartridges (Waters,
Waltham, MA, USA) and eluted in 500ml of mobile phase.
A quantity of 100ml of the samples was directly injected into
an HPLC system composed of a Waters 600 controller pump, a
Waters C18 (particle size 4mm) column, a Waters 717 plus
autosampler and a Bioanalytical Systems LC-4A electrochemical
detector (set at a holding potential of 0·65 mV and a sensitivity
of 1 nA). An isocratic elution was used: the mobile phase
consisted of a solution of 25 mM-Na2HPO4 with 6 % of methanol
(pH 3·55), running at a flux of 1·0 ml/min. The signal coming out
of the detector was fed to an analogue to digital converter
controlled by Peak Sample Chromatography System Software
(Buck Scientific, East Norwalk, CT, USA). Identification and
quantification of catecholamines were done against external
standards.
Measurement of total hepatic glutathione
Glutathione is the major intracellular non-protein thiol and an
important protector against free radical damage. We tested the
effects of caffeine on hepatic reduced glutathione stores since
it is known that total glutathione is significantly depleted after
exposure to oxidative stress and increases in the presence of
antioxidant compounds. A sample of the medium lobe of the
liver was collected after an abdominal laparotomy and stored
at 2808C in an ultra-low freezer (Heraeus, Madrid, Spain).
Approximately 100 mg of the tissue was weighed and
homogenised in metaphosphoric acid (5 %) using a Teflon
pestle. The homogenate was centrifuged at 12 000 g for 10 min
at 48C and the supernatant fraction was collected and frozen
at2808C for future use. Total hepatic glutathione was quantified
using an enzymic method (HT Glutathione Assay Kit, no. 7511-
100-K; Trevigen European, Amsbio, Abingdon, Oxon, UK).
Collection and weight of abdominal fat
Renal, genital and visceral fat was collected after an abdominal
laparotomy and weighed.
Drugs and chemicals
Caffeine, paraxanthine, theobromine, theophyline, bovine
serum albumin, KH2PO4, KOH, metaphosphoric acid,
Na2HPO4, noradrenaline, adrenaline, perchloric acid and Tris
were obtained from Sigma-Aldrich (Madrid, Spain). Sucrose
was obtained from Panlab. Insulin was commercially available
as Humulinw Regular (Lilly, Algés, Portugal) in a concentration
of 100 UI/ml (4·5 mg/ml). CVD was kindly provided by
Labesfal (Lisbon, Portugal).
Data analysis
Data were evaluated using Graph Pad Prism Software, version
4 (GraphPad Software Inc., San Diego, CA, USA) and was
presented as mean values with their standard errors. The
significance of the differences between the mean values was
calculated by one- and two-way ANOVA with Dunnett’s and
Bonferroni multiple comparison tests, respectively. Potential

















relationships between the variables under analysis were
explored using Pearson’s correlation coefficient. Differences
were considered significant at P#0·05.
Results
The ingestion of caffeine in drinking water (1 g/l) was stable
throughout the experiments in all the groups since there
were no significant changes in individual daily liquid intake
per kg. Liquid intake in the Caff group was 6·78 (SEM 0·50)
ml/kg per d, which was not significantly different from control
(7·23 (SEM 0·27) ml/kg per d). Liquid intake in the HF and HSu
groups was 5·83 (SEM 0·25) and 8·31 (SEM 0·40) ml/kg per d,
respectively. Liquid intake in the HFCaff and HSuCaff groups
was 6·01 (SEM 0·19) and 8·08 (SEM 0·68) ml/kg per d, respect-
ively. No significant differences were observed within the
groups. Food intake was also not significantly different (con-
trol, 57·78 (SEM 2·05); Caff, 55·03 (SEM 5·25); HF, 62·56 (SEM
1·99); HFCaff, 60·58 (SEM 2·79); HSu, 51·22 (SEM 4·51); HSuCaff,
52·78 (SEM 3·81) mg/kg per d).
As expected we did not detect the presence of caffeine or its
metabolites in control, HF and HSu groups. Plasma caffeine
concentration in the Caff group was 3·73 (SEM 1·08) mg/ml,
in the HFCaff group 3·23 (SEM 1·09) mg/ml and 4·34
(SEM 1·15) mg/ml in the HSuCaff group. These values
were not significantly different and are within the range of
0·37–5·95mg/ml previously described by Gasior et al. for
doses of 0·25–1 mg/ml of caffeine in drinking water in
rats(30). Although we did not monitor the physical activity of
the animals we did not observe any behavioural changes
during the period of caffeine ingestion.
Fasting glycaemia was not significantly different in control
andHFgroups although theHSudiet significantly increased fast-
ing glycaemia in comparison with the control group (P,0·001)
(Table 1). Chronic caffeine intake did not modify fasting glycae-
mia both in the control and HF rats but it reversed hyperglycae-
mia induced by the HSu diet (P,0·05) (Table 1).
Fasting insulinaemia was 1·80 (SEM 0·50) mg/l in control rats.
Chronic caffeine intake did not significantly change basal insu-
lin concentrations in control rats. Both the HF and HSu diets
caused a significant increase in plasma insulin levels
(P,0·001; Table 1) in comparison with the control group.
This effect was reduced to control values by chronic caffeine
intake in HF (P,0·001) but not in HSu rats (Table 1).
Effect of chronic caffeine intake on insulin sensitivity
Fig. 1 represents the effect of chronic caffeine intake (1 g/l) on
insulin sensitivity in control, HF and HSu groups. The HF diet
induced a decrease in KITT from a control value of 4·49 (SEM
0·43) % glucose/min to 3·02 (SEM 0·34) % glucose/min
(P,0·05). The HSu diet decreased KITT to 2·68 (SEM 0·32) % glu-
cose/min (P,0·01). Chronic caffeine intake did not modify
insulin sensitivity in control animals (KITT Caff ¼ 4·52 (SEM
0·23) % glucose/min). In both the HF and HSu diet groups,
chronic caffeine intake completely reversed the insulin resist-
ance induced by the diets (KITT HFCaff ¼ 4·26 (SEM 0·16) %
glucose/min; KITT HSuCaff ¼ 4·07 (SEM 0·26) % glucose/min).
Effect of chronic caffeine intake on mean arterial pressure
Fig. 2 displays the effect of chronic caffeine consumption
on MAP in control, HF and HSu animals. HF and HSu
administration induced a significant increase in MAP
compared with controls (MAP control ¼ 85·99 (SEM 2·15)
mmHg; MAP HF ¼ 108·04 (SEM 5·30) mmHg; MAP
HSu ¼ 104·69 (SEM 2·72) mmHg). Chronic caffeine intake did
not modify MAP in control animals; however, when admini-
strated to HF and HSu rats, it completely prevented the
hypertension induced by both diets (MAP Caff ¼ 85·53 (SEM
5·32) mmHg; MAP HFCaff ¼ 86·92 (SEM 3·96) mmHg; MAP
























Fig. 1. Effect of chronic caffeine intake (1 g/l) on insulin sensitivity in control,
high-fat (HF) and high-sucrose (HSu) diet rats, determined by the insulin
tolerance test, expressed as constant rate for glucose disappearance (KITT).
(A), Without caffeine (n 9–12); (B), with caffeine (n 12–15). Values are
means, with standard errors represented by vertical bars. Mean value was
significantly different from that of the control rats not given caffeine:
*P,0·05, **P,0·01 (two-way ANOVA with Bonferroni multiple comparison
test). Mean value was significantly different from that of the rats within the
same diet group not given caffeine: † P,0·05, †† P,0·01 (two-way ANOVA
with Bonferroni multiple comparison test).
Table 1. Effect of chronic caffeine intake (1 g/l) on glycaemia and insuli-
naemia in control rats and in rats fed high-fat and high-sucrose diets
(Mean values with their standard errors for all the individual samples





Treatment Mean SEM Mean SEM
Control
Without caffeine 1004 42·2 1·80 0·50
With caffeine 1022 27·1 0·78 0·16
High-fat diet
Without caffeine 1049 26·2 5·48*** 0·22
With caffeine 1019 40·7 1·84‡‡‡ 0·53
High-sucrose diet
Without caffeine 1458*** 95·6 5·26*** 0·28
With caffeine 1181† 48·6 4·74 0·48
*** Mean value was significantly different from that of the control rats (P,0·001;
two-way ANOVA with Bonferroni multiple comparison test).
† Mean value was significantly different from that of the rats fed the high-sucrose
diet without caffeine (P,0·05; two-way ANOVA with Bonferroni multiple compari-
son test).
‡‡‡ Mean value was significantly different from that of the rats fed the high-fat
diet without caffeine (P,0·001; two-way ANOVA with Bonferroni multiple com-
parison test).

















Effect of chronic caffeine intake on body weight, visceral
fat and NEFA
Fig. 3 represents the effects of chronic caffeine intake on
weight gain (Fig. 3(a)), visceral fat (Fig. 3(b)) and serum
NEFA (Fig. 3(c)). The HF diet caused a significant increase
in weight gain per d compared with control animals, whereas
the HSu diet did not (control ¼ 1·53 (SEM 0·26) g/d; HF ¼ 4·32
(SEM 0·45) g/d; HSu: 2·66 (SEM 0·25) g/d). Caffeine intake did
not significantly modify weight gain either in control or in
HSu animals (Caff ¼ 1·14 (SEM 0·16) g/d; HSuCaff ¼ 2·51
(SEM 0·29) g/d). In contrast, caffeine administration signifi-
cantly reduced weight gain to 2·39 (SEM 0·36) g/d in HF
animals (Fig. 3(a)).
The HF diet significantly increased visceral fat compared
with control animals (control ¼ 8·48 (SEM 0·63) g/kg;
HF ¼ 12·70 (SEM 0·64) g/kg) while the HSu diet did not
(10·99 (SEM 0·86) g/kg). Caffeine consumption in control
and HSu animals did not significantly modify visceral
fat (Caff ¼ 6·91 (SEM 0·40) g/kg; HSuCaff ¼ 9·91 (SEM 0·97)
g/kg) but the effect was significant in the HFCaff group
(7·80 (SEM 0·90) g/kg), a value similar to control (Fig. 3(b)).
Fig. 3(c) shows that while the HF diet did not alter serum
NEFA (NEFA control ¼ 389·14 (SEM 40·45) mM; NEFA
HF ¼ 436·45 (SEM 36·23) mM), the HSu diet significantly
increased NEFA to 940·62 (SEM 89·66) mM. Chronic caffeine
intake did not modify NEFA either in control or in HF animals
(NEFA Caff ¼ 406·57 (SEM 29·55) mM; NEFA HFCaff ¼ 391·67
(SEM 38·23) mM); however, it significantly decreased NEFA in
the HSu group to 610·24 (SEM 41·06) mM. The correlations
between both KITT and visceral fat and KITT and NEFA, with
and without caffeine treatment, are depicted in Fig. 4. We
observed a statistically significant negative correlation
between KITT and visceral fat (r 2 0·467; P ¼ 0·0071) that is
lost upon chronic caffeine treatment (r 2 0·181; P ¼ 0·314;
Fig. 4(a)). Similarly, a statistically significant correlation was
observed between KITT and serum NEFA (r 2 0·444;
P ¼ 0·014) and this correlation was lost in the caffeine-treated
groups (r 2 0·148; P ¼ 0·338; Fig. 4(b)).
Effect of chronic caffeine intake on total hepatic
glutathione and plasma NO/NO3
2 concentration
Fig. 5(a) shows that the HF and HSu diets significantly
decreased the total hepatic glutathione content by 35·37 and
70·40 %, respectively, from a control value of 75·3 (SEM 3·85)
nmol/mg tissue. Chronic caffeine administration did not
significantly modify hepatic glutathione þ glutathione disul-
fide (GSSG) levels (Caff ¼ 83·6 (SEM 7·46) nmol/mg tissue;
HFCaff ¼ 59·1 (SEM 7·55) nmol/mg tissue; HSuCaff ¼ 35·3
(SEM 3·28) nmol/mg tissue).
Fig. 5(b) represents the effect of chronic caffeine intake on
plasma NO/NO3
2. The HF diet caused a significant increase in
plasma NO/NO3
2 compared with control animals, whereas the
HSu diet did not (control, 15·4 (SEM 1·0) mM; HF, 24·1 (SEM 2·4)
mM; HSu, 12·9 (SEM 1·0) mM). Caffeine intake did not modify
plasma NO/NO3
2 in any of the groups tested (Caff, 17·3 (SEM
0·7) mM; HFCaff, 22·0 (SEM 1·8) mM; HSuCaff, 14·8 (SEM 1·2) mM).
Effect of chronic caffeine intake on serum catecholamines
The effect of chronic caffeine intake on serum catecholamines





















Fig. 2. Effect of chronic caffeine intake (1 g/l) on mean arterial pressure
(MAP) in control, high-fat (HF) and high-sucrose (HSu) diet rats. (A), Without
caffeine (n 9–12); (B), with caffeine (n 9–15). Values are means, with stan-
dard errors represented by vertical bars. ** Mean value was significantly
different from that of the control rats not given caffeine (P,0·01; two-
way ANOVA with Bonferroni multiple comparison test). Mean value was
significantly different from that of the rats within the same diet group not























































Fig. 3. Effect of chronic caffeine intake (1 g/l) on body-weight increment, calculated as total weight variation during the experimental period (a), visceral fat,
weighed post-mortem and corrected to body weight (b) and serum NEFA (c) in control, high-fat (HF) and high-sucrose (HSu) diet rats. (A), Without caffeine (n
10–12, n 9–12 and n 9–12 for body-weight increment, visceral fat and NEFA, respectively); (B), with caffeine (n 12–16, n 9–13 and n 10–15 for body-weight
increment, visceral fat and NEFA, respectively). Values are means, with standard errors represented by vertical bars. Mean value was significantly different from
that of the control rats not given caffeine: ** P,0·01, *** P,0·001 (two-way ANOVA with Bonferroni multiple comparison test). ††† Mean value was significantly
different from that of the rats within the same diet group not given caffeine (P,0·001; two-way ANOVA with Bonferroni multiple comparison test).

















represented in Fig. 6(a). The HSu and HF diets significantly
increased plasma catecholamines by 211·9 and 124·1 %,
respectively, from a control value of 50·03 (SEM 6·91) mM.
Chronic caffeine intake did not modify plasma catecholamines
in control animals; however, when administered together with
the HSu and HF diets, caffeine prevented the increase in circu-
lating catecholamines, suggesting that the metabolic and hae-
modynamic effects of chronic caffeine intake are mediated by
a decrease in sympathetic activation. Moreover, KITT was
negatively correlated with plasma catecholamines both in
the absence (r 20·399; P¼0·0484) and presence (r 20·419;
P¼0·009) of caffeine treatment (Fig. 6(b)).
Effect of carvedilol on insulin sensitivity and mean arterial
pressure
There were no significant changes in individual daily liquid
intake per kg in any of the groups tested. Food intake was
also not significantly different (data not shown). In the
HFMC group there was a decrease in KITT from a control
value of 4·90 (SEM 0·26) % glucose/min to 3·50 (SEM 0·23) %
glucose/min. The HSuMC diet decreased KITT to 3·35 (SEM
0·19) % glucose/min. CVD did not modify insulin sensitivity
in control animals (KITT CVD ¼ 4·68 (SEM 0·30) % glucose/
min) but it completely reversed the insulin resistance induced
by the diets (KITT HFCVD ¼ 4·64 (SEM 0·27) % glucose/min;
KITT HSuCVD ¼ 5·20 (SEM 0·12) % glucose/min) (Fig. 7(a)).
CVD significantly decreased fasting glycaemia in the HSuMC
group from 1165 (SEM 45·6) to 919 (SEM 27·5) mg/l. Both the
HFMC and HSuMC diets caused a significant increase in
plasma insulin levels in comparison with the MC group and
this effect was reversed by CVD administration (MC ¼ 2·45
(SEM 0·26) mg/l; HFMC ¼ 4·88 (SEM 0·30) mg/l; HSuMC ¼ 4·36
(SEM 0·37) mg/l; HFCVD ¼ 2·42 (SEM 0·42) mg/l; HSuCVD ¼ 1·76
(SEM 0·79)mg/l). We also observed that CVD completely restored
MAP to control values in HF and HSu rats, as expected due
to its anti-hypertensive action (MC ¼ 95·6 (SEM 3·79) mmHg;
CVD ¼ 97·2 (SEM 3·35) mmHg; HFMC ¼ 113·0 (SEM 4·07)
mmHg; HFCVD ¼ 99·4 (SEM 4·59) mmHg; HSuMC ¼ 113·6 (SEM
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Fig. 4. Effect of chronic caffeine intake (1 g/l) on the correlations between insulin sensitivity, visceral fat and NEFA in all the animals tested. (a) Caffeine eliminates
the correlation between constant rate for glucose disappearance (KITT) and visceral fat mass. (b) Caffeine eliminates the correlation between KITT and serum
NEFA. Pearson correlation coefficient was in (a): r 20·467, P¼0·0071 without caffeine (A, - - -) and r 20·181, P¼0·314 with caffeine (B, – –); in (b): r 20·444,









































Fig. 5. Effect of chronic caffeine intake (1 g/l) on biomarkers of oxidative status. (a) Effect of caffeine on total hepatic glutathione in control rats and in rats sub-
mitted to high-fat (HF) and high-sucrose (HSu) diets. (b) Effect of caffeine on plasma NO/NO3
2 in control, HF and HSu rats. (A), Without caffeine (n 8–11 and
n 8–13 for glutathione and NO, respectively); (B), with caffeine (n 8–12 and n 6–12, for glutathione and NO, respectively). Values are means, with standard
errors represented by vertical bars. Mean value was significantly different from that of the control rats not given caffeine: **P , 0·01, ***P , 0·001 (two-way
ANOVA with Bonferroni multiple comparison test).

















Effect of carvedilol on serum catecholamines
The HSuMC and HFMC groups showed a significant increase
in plasma catecholamines of 112·4 and 97·9 %, respectively,
from a control value of 58·53 (SEM 8·88) mM in the MC
group. In contrast with caffeine, CVD treatment did not
modify plasma catecholamines in any of the groups tested
(CVD, 59·2 (SEM 17·80) mM; HFCVD, 108·6 (SEM 33·14) mM;
HSuCVD, 88·8 (SEM 32·26) mM; Fig. 7(b)). CVD administration
did not significantly modify weight gain, visceral fat, NEFA,
hepatic glutathione or NO/NO3
2 in any of the disease
models tested (data not shown).
Discussion
We demonstrated in the present study that chronic caf-
feine intake prevents the development of insulin resistance
and hypertension in high-fat- and high-sucrose-fed rats and
induces a pronounced decrease in circulating adrenaline and
noradrenaline. Also, the effect of CVD, an antagonist of b1,
b2 and a1 adrenoceptors, on insulin sensitivity mimicked
the effect of caffeine, supporting the hypothesis that caffeine’s
beneficial effects are mediated by the inhibition of the sym-
pathetic nervous system.
Chronic caffeine treatment did not significantly change fast-
ing glycaemia both in the control and HF groups, which were
normoglycaemic without caffeine treatment(33), but it totally
reversed the hyperglycaemia induced by the HSu diet. Also, in
contrast with the acute effects of caffeine on insulin secretion
described in the literature(12), the present results show that
plasma insulin levels significantly decreased in the HFCaff
group and trend towards a decrease in the HSuCaff group com-
pared with the HF and HSu groups, respectively. In the HFCaff
group the reduction of fasting insulinaemia, accompanied by an
increase in KITT, indicates that chronic caffeine not only
increased insulin sensitivity but also normalised insulin
secretion in the HF animals. We do not know at this point if











































Fig. 7. Effect of carvedilol (CVD, 0·2 g/l) and its vehicle, methylcellulose (MC, 0·5 %), on insulin sensitivity and plasma catecholamines in control, high-fat (HF) and
high-sucrose (HSu) diet rats. (a) The effect of CVD on insulin sensitivity was determined by the insulin tolerance test and is expressed as constant rate for glucose
disappearance (KITT). (A), MC (n 10–17); (B), CVD (n 7–12). Values are means, with standard errors represented by vertical bars. Mean value was significantly
different from that of the control rats given MC: *P , 0·05, **P , 0·01 (two-way ANOVA with Bonferroni multiple comparison test). Mean value was significantly
different from that of the rats within the same diet group given MC: †P , 0·05, †††P , 0·001 (two-way ANOVA with Bonferroni multiple comparison test).
(b) Effect of CVD on catecholamine (adrenaline plus noradrenaline) plasma levels. (A), MC (n 10–36); (B), CVD (n 5–7). Values are means, with standard errors


















































Fig. 6. Effect of chronic caffeine intake (1 g/l) on plasma catecholamine concentration in control, high-sucrose (HSu) and high-fat (HF) diet rats. (a) Effect of
caffeine on catecholamine (adrenaline plus noradrenaline) plasma levels. (A), Without caffeine (n 10–16); (B), with caffeine (n 12–16). Values are means, with
standard errors represented by vertical bars. Mean value was significantly different from that of the control rats not given caffeine: **P,0·01, ***P,0·001 (two-
way ANOVA with Bonferroni multiple comparison test). Mean value was significantly different from that of the rats within the same diet group not given caffeine:
††P,0·01, ††† P,0·001 (two-way ANOVA with Bonferroni multiple comparison test). (b) Caffeine treatment does not change the correlation between constant
rate for glucose disappearance (KITT) and circulating catecholamine (adrenaline plus noradrenaline) plasma levels. Pearson correlation coefficient was r 20·399,
P¼0·0484 without caffeine (W) and r 20·419, P¼0·009 with caffeine (X). Data represent all the individual samples obtained from control, HF and HSu rats.

















on the pancreas, or simply a negative-feedback mechanism
induced by improved peripheral insulin sensitivity at the
b-cell. However, previous studies in human subjects have
described that caffeinated coffee consumption leads to a
reduction of plasma C-peptide concentrations in healthy and
in obese women, suggesting that coffee components decrease
insulin secretion(16) and in vitro studies also showed that adeno-
sine regulates insulin secretion by the b-cell(34).
In contrast with the HFCaff animals, in the HSuCaff group
caffeine restored insulin sensitivity and normoglycaemia but
the animals remained hyperinsulinaemic compared with con-
trols. This suggests that in the caffeine-treated sucrose-fed
model, insulin action improved sufficiently to maintain glu-
cose homeostasis but not enough to normalise endogenous
insulin secretion.
In the HF rats both visceral fat and weight gain increased sig-
nificantly and caffeine reversed these effects, in agreement with
the literature(12). Weight loss and visceral fat mass decrease
induced by long-term caffeine consumption may have been
due to increased lipolysis accompanied by increased NEFA oxi-
dation, since circulating NEFA were not elevated compared
with control animals. We observed no changes in weight gain
or visceral fat mass in the HSu rat treated with caffeine. These
results indicate that increased adipose tissue mass is not contri-
buting to insulin resistance in this animal model, which is in
accordance with previous results by Kanazawa’s group(35).
In contrast to the HF diet, the HSu diet increased circulating
NEFA, indicating augmented lipolysis or decreased NEFA oxi-
dation in the sucrose-fed rats as previously described by
others(36). These results may also be due to an increased
de novo lipogenesis in adipocytes and liver in this model
which, combined with insulin resistance, may lead to enhanced
lipolysis and systemic NEFA(37). We have observed that chronic
caffeine intake reversed the increase in NEFA induced by the
HSu diet. This effect may be related to an augmented activity
of 50-AMP activated protein kinase (AMPK) induced by caffeine
that promotes an enhancement in NEFA uptake and oxidation in
skeletal muscle(38,39). Recently, it has also been shown that caf-
feine can increase GLUT-4 mRNA in skeletal muscle cells and
insulin-independent glucose transport mediated by AMPK(38),
which may explain the return to normal glycaemia observed
in the caffeine-treated rats. Despite the beneficial effects of caf-
feine on visceral fat in the HF-fed rat and in circulating NEFA in
the HSu rat, the correlation analyses show that insulin action
loses its dependence of these variables after caffeine treatment.
The insulin-sensitising effect of chronic caffeine treatment
may also be directly related to antagonism of adenosine
receptors on insulin target tissues. The effect of adenosine on
glucose homeostasis is currently a hot-topic area with con-
troversial results: while positive effects of A1 receptor partial
agonists are well documented on adipose tissue glucose
uptake(40), studies using adenosine receptor antagonists have
shown increases(41), decreases(42) and no effect(43) of these
drugs on skeletal muscle glucose uptake. Also, A2B receptor
antagonists have been used to increase plasma insulin levels
in vivo (44) and more recently to reduce insulin resistance(45).
Clearly, more studies are required to clarify the role of adeno-
sine receptors on glucose homeostasis.
In the present study we also demonstrated that chronic
caffeine intake prevents the development of hypertension
in HF- and HSu-fed animals. Recently, it has been shown
that endothelium-dependent vasodilatation after long-term
caffeine administration is enhanced in young healthy
men(46), a mechanism by which caffeine treatment could
lower blood pressure. However, we did not find any effect
of chronic caffeine consumption on NO production, sug-
gesting that NO is involved neither in the prevention of
hypertension nor in insulin resistance induced by caffeine.
It has also been suggested that caffeine may prevent oxidative
damage(47,48) which could improve endothelium-dependent
vasodilation and insulin action. However, in our experimental
setting we observed no changes in total hepatic glutathione,
both in HF- and HSu-treated animals. Hepatic glutathione
stores are significantly depleted after exposure to oxidative
stress(49) and if administration of caffeine produced signifi-
cant antioxidant effects, we would expect intracellular hepatic
glutathione levels to rise, which did not happen.
Chronic caffeine treatment caused a decrease in circulating
catecholamines, suggesting that decreased sympathetic ner-
vous system activation, either at the adrenal medulla or at
the sympathetic nerves innervating blood vessels, is involved
in the protective effects of caffeine. Adenosine receptor ago-
nists inhibit sympathetic neurotransmission and catecholamine
release in several tissues, including the hippocampus(50)
and adrenal chromaffin cells(51), when administered acutely.
Adenosine receptor antagonists, such as caffeine, increase
plasma renin activity, adrenaline and noradrenaline(52) after
acute administration; however, in accordance with the present
results, it has been shown that the increase in adrenaline
levels induced by a single dose of caffeine is lost with
sustained consumption(53).
The present results also show that the adrenergic antago-
nist, CVD, mimicked the effects of caffeine. As observed with
caffeine treatment, CVD totally reversed the hyperglycaemia
induced by the HSuMC diet. Plasma insulin levels significantly
decreased after CVD treatment in the HFCVD and HSuCVD
groups, in contrast to the hypoinsulinaemic effect of caffeine
that was observed in the HFCaff but not in the HSuCaff
group. Others have also reported that CVD, among other
third-generation b-blockers, lack adverse metabolic effects
and may actually produce favourable effects on insulin sensi-
tivity(54,55). The mechanisms behind these findings are not yet
fully understood but the role of the a1 and b2 adrenoceptor
blocking effects of CVD appears to be crucial(56). While caffeine
significantly decreased weight gain and visceral fat mass
in HF rats and circulating NEFA in HSu rats, CVD treatment
did not change any of these factors in the experimental
groups, although the effect of both drugs on insulin sensitivity
was very similar. These results are consistent with the hypo-
thesis that the insulin-sensitising properties of both caffeine
and CVD are not directly related with changes in adipose
tissue homeostasis. Finally, CVD has also been reported to
increase endogenous NO production(57,58), affecting endo-
thelium-dependent vasodilation, a mechanism by which this
drug could increase insulin sensitivity(59,60). We did not find
any effect of CVD on NO production in our experimental

















conditions, suggesting that NO is involved neither in the pre-
vention of hypertension nor in insulin sensitisation induced
by CVD.
In conclusion, chronic caffeine administration prevents
the development of insulin resistance and hypertension in
high-fat- and high-sucrose-fed animals due to a decrease in
circulating catecholamines. Treatment with an adrenergic
antagonist mimics the protective effects of caffeine against
diet-induced insulin resistance by blockade of adrenergic
receptors without changes in serum catecholamine concen-
tration. The exact biological mechanism underlying the
decrease in circulating catecholamines induced by caffeine
remains to be clarified and may involve alterations in the
expression of adenosine receptors as well as in the expression
of other neurotransmitter receptors and ionic channels(61,62).
In conclusion, we have shown that long-term caffeine
administration has a protective effect on the development of
diet-induced insulin resistance and hypertension in rats. Our
work strengthens the conclusions of recent epidemiological
studies concerning the protective role of coffee consumption
in type 2 diabetes and the metabolic syndrome and helps to
support the need for a paradigm shift on advised lifestyle
changes, like coffee withdrawal, in insulin-resistant and hyper-
tensive patients.
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